EXACT Therapeutics AS Logo

EXACT Therapeutics AS

Biopharma firm using ultrasound to enhance drug delivery for oncology via its ACT® platform.

EXTX | OL

Overview

Corporate Details

ISIN(s):
NO0010852205 (+1 more)
LEI:
2138006ZE5JAL39AGD55
Country:
Norway
Address:
Østre Aker vei 19, 0581 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

EXACT Therapeutics AS is a clinical-stage biopharmaceutical company developing a technology platform for targeted therapeutic enhancement called Acoustic Cluster Therapy (ACT®). The company's vision is to become a leading precision medicine company by utilizing ultrasound to improve drug delivery in oncology. The proprietary ACT® platform uses a biomechanical mode of action to increase the uptake of co-administered drugs from blood vessels into the surrounding cancer tissue without damaging capillary walls. This technology is designed to be compatible with existing hospital ultrasound systems, requires no drug reformulation, and has shown potential in targeting tumors and crossing the blood-brain barrier. A key focus area is pancreatic cancer, with a clinical program in Phase 2 trials.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-25 12:57
Investor Presentation
EXACT Therapeutics to present company update - Attachment: 251125 Exact Therap…
English 1.5 MB
2025-11-25 12:57
Report Publication Announcement
EXACT Therapeutics to present company update
English 1.1 KB
2025-11-24 08:25
Director's Dealing
EXACT Therapeutics AS: New option program and receipt of share options by prima…
English 112.5 KB
2025-11-24 08:25
Remuneration Information
EXACT Therapeutics AS: New option program and receipt of share options by prima…
English 2.2 KB
2025-09-25 08:00
Interim / Quarterly Report
EXACT Therapeutics first half 2025 interim results - Attachment: EXACT Therape…
English 743.7 KB
2025-09-25 08:00
Report Publication Announcement
EXACT Therapeutics first half 2025 interim results
English 1.4 KB
2025-09-18 08:00
Regulatory Filings
EXACT Therapeutics’ Phase 2 trial to be presented at the 2025 AACR Special Conf…
English 2.0 KB
2025-09-09 08:00
Regulatory Filings
EXACT Therapeutic’s Acoustic Cluster Therapy to be presented at the Ninth Inter…
English 2.0 KB
2025-08-12 08:30
Regulatory Filings
EXACT Therapeutics to Present at the European Society for Medical Oncology (ESM…
English 1.8 KB
2025-08-11 11:08
Report Publication Announcement
Financial calendar
English 430 bytes
2025-07-08 08:30
Legal Proceedings Report
EXACT Therapeutics announces grant of core patent in the U.S.
English 1.9 KB
2025-06-24 08:00
Regulatory Filings
EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients w…
English 3.0 KB
2025-06-13 12:09
Director's Dealing
EXACT Therapeutics AS: Primary insider notification - Attachment: Notification …
English 41.4 KB
2025-06-13 12:09
Board/Management Information
EXACT Therapeutics AS: Primary insider notification
English 1.3 KB
2025-06-13 12:05
AGM Information
EXACT Therapeutics minutes from Annual General Meeting June 13, 2025 - Attachme…
Norwegian 729.7 KB

Automate Your Workflow. Get a real-time feed of all EXACT Therapeutics AS filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for EXACT Therapeutics AS

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for EXACT Therapeutics AS via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Developing targeted AAV genetic medicines for large market eye, lung, and heart diseases.
United States of America
FDMT
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Develops medical devices, diagnostics, nutritionals, and pharmaceuticals for global health.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
AbCellera Biologics Inc. Logo
An AI-powered platform that discovers and develops antibody therapeutics for pharma partners.
United States of America
ABCL
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea
174900

Talk to a Data Expert

Have a question? We'll get back to you promptly.